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Abstract
Background: Current literature suggests that dipeptidyl peptidase IV (DPP-IV; CD26) plays an
essential role in T-dependent immune responses, a role that could have important clinical
consequences. To rigorously define the role of DPP-IV in the immune system, we evaluated genetic
and pharmacological inhibition of the enzyme on T-dependent immune responses in vivo.
Results: The DPP-IV null animals mounted robust primary and secondary antibody responses to
the T dependent antigens, 4-hydroxy-3-nitrophenylacetyl-ovalbumin (NP-Ova) and 4-hydroxy-3-
nitrophenylacetyl-chicken gamma globulin (NP-CGG), which were comparable to wild type mice.
Serum levels of antigen specific IgM, IgG1, IgG2a, IgG2b and IgG3 were similar between the two
groups of animals. DPP-IV null animals mounted an efficient germinal center reaction by day 10 after
antigen stimulation that was comparable to wild type mice. Moreover, the antibodies produced by
DPP-IV null animals after repeated antigenic challenge were affinity matured. Similar observations
were made using wild type animals treated with a highly selective DPP-IV inhibitor during the entire
course of the experiments. T cell recall responses to ovalbumin and MOG peptide, evaluated by
measuring proliferation and IL-2 release from cells isolated from draining lymph nodes, were
equivalent in DPP-IV null and wild type animals. Furthermore, mice treated with DPP-IV inhibitor
had intact T-cell recall responses to MOG peptide. In addition, female DPP-IV null and wild type
mice treated with DPP-IV inhibitor exhibited normal and robust in vivo cytotoxic T cell responses
after challenge with cells expressing the male H-Y minor histocompatibility antigen.
Conclusion: These data indicate Selective inhibition of DPP-IV does not impair T dependent
immune responses to antigenic challenge.
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Background
DPP-IV (CD26) is a cell surface 110 kDa glycoprotein
expressed on epithelial cells and leukocyte subsets pos-
sessing dipeptidyl peptidase activity. [1]. The DPP-IV
enzyme is known to cleave the N-terminal dipeptide from
the incretin hormones glucagon-like peptide-1 (GLP-1)
and glucose-dependent insulinotropic polypeptide (GIP).
This cleavage inactivates the hormones thereby neutraliz-
ing their prandial insulinotropic effect [2,3]. Targeting the
dipeptidyl peptidase activity with low molecular weight
enzyme inhibitors restores incretin activity and has led to
the successful development of a DPP-IV inhibitor, sit-
agliptin, as an effective therapy for Type 2 diabetes [3]. A
concern regarding the potential for DPP-IV inhibitors to
affect immune function and increase infection rates has
been raised [4,5], although a recently published analysis
of safety using pooled source data showed no significant
difference in the incidence of overall or specific types of
infection [6].
The role of DPP-IV enzymatic activity in immune function
has not been extensively studied, however there are a few
reports suggesting that DPP-IV can modulate immune
responses [7,8]. Cell culture studies have implicated DPP-
IV as a co-receptor in T cell activation [1]. In addition,
DPP-IV may affect leukocyte trafficking via cleavage of cer-
tain chemokines such as SDF-1 [9]. DPP-IV null animals
were shown have reduced humoral immune responses to
pokeweed mitogen [10]. In an Ova asthma model, rats
expressing a truncated inactive form of DPP-IV due to a
genetic polymorphism were shown to have reduced T cell
recruitment to the lungs and decreased Ova-specific IgE
titers [11]. However, studies with DPP-IV deficient ani-
mals do not directly address the role of the dipeptidyl
peptidase activity as this cell surface protein may possess
other non-enzymatic functions [12-14]. In addition, some
reports that attributed immunomodulatory effects to
DPP-IV enzymatic activity may have been confounded by
use of non-selective inhibitors. Indeed, we have previ-
ously shown that blockade of T cell activation in vitro cor-
relates with inhibitor activity directed against DPP8/9 but
not against DPP-IV [15]. Moreover, inhibitors that were
previously reported to modulate T cell responses were
found to be potent inhibitors of DPP8/9 activity [16-21].
To extend these observations to an in vivo setting in order
to better characterize any potential role of DPP-IV in
immune function, we investigated the T cell-dependent
responses in mice using genetic ablation or pharmacolog-
ical blockade of DPP-IV. T cell-dependent antibody
responses provides a useful model for addressing immune
competence as it is dependent on many factors such as
antigen processing and presentation, CD4 T cell help, ger-
minal center reactions, B cell activation and differentia-
tion, affinity maturation, and memory cell formation. We
report here that genetic ablation or specific inhibition of
DPP-IV did not impair T cell-dependent antibody
responses. In addition, we find that genetic ablation or
specific inhibition of DPP-IV did not compromise cyto-
toxic T cell function in vivo.
Methods
Mice
Female 8 week old C57Bl/6J and DPP-IV-/- [22] mice were
obtained from Taconic Laboratory, (Taconic Laboratories,
Tarrytown, NY, USA). The DPP-IV-/- mice were originally
obtained from Dr. D Marguet and backcrossed on C57BL/
6 to homogeneity [23]. SNP testing carried out revealed
98.4% B6J background. The knock out animals were gen-
erated by mating male and female homozygous null ani-
mals. The control animals were age-matched and
obtained from the same facility as the null animals. Ani-
mal were housed in a specific pathogen-free rodent facil-
ity. All animal protocols were approved by the Merck
Institutional Animal Care and Use Committee.
Antibodies and reagents
To quantify mouse immunoglobulins by ELISA, the fol-
lowing secondary antibodies were used as per manufac-
tures instructions: Rat anti-mouse lambda-Biotin, anti-
mouse kappa-Biotin, Rat anti-mouse IgG1-Biotin (BD
Biosciences, San Jose, CA, USA), Goat anti-mouse IgG2a-
Biotin, Rat anti-mouse IgG2b-Biotin, Goat anti-mouse
IgG3-Biotin, and Rat anti-mouse IgM-Biotin (Southern
Biotechnology Associate Inc., Birmingham, AL, USA). (4-
hydroxy-3-nitrophenyl) acetyl-chicken γ-globulin (NP-
CGG, NP-BSA and Ovalbumin) were obtained from Bio-
search Technologies, Novato, CA, USA.
MOG p35–55 was obtained from Sigma-Aldrich, St.
Louis, MO, USA. Heat-killed Mycobacterium tuberculosis
was obtained from BD Diagnostics, Franklin Lakes, New
Jersey, USA. Pertussis toxin was obtained from List Biolog-
ical Laboratories, Campbell, CA, USA. The highly selective
DPP-IV inhibitor, des-fluro sitagliptin, was synthesized as
previously described [24]. To deliver an effective dose of
~400 mg/kg daily, mice were fed a diet consisting of 6.7 g
of this compound per 1 kg Tekland chow (Research diets,
New Jersey, USA). The enzyme activity of DPP-IV in the
blood was assayed as described earlier [15].
T cell-dependent antibody responses
Mice were immunized i.p. with 100 μg of NP-CGG in
alum for the primary immunization, and 100 μg of NP-
CGG in PBS i.p. for the secondary immunization [25].
Mice were bled via the retro orbital sinus at indicated
times and the levels of anti-NP and CGG antibodies and
their isotypes were determined by ELISA as described pre-
viously [26,27]. Briefly, mouse serum antibodies were
immobilized onto 96-well plates coated with NP-BSA orBMC Immunology 2009, 10:19 http://www.biomedcentral.com/1471-2172/10/19
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CGG and detected with biotin-conjugated anti-mouse
immunoglobulins. The assays were developed using
streptavidin-europium and plates were read on Victor 2
1420 multilabel counter (Perkin Elmer, Waltham, MA,
USA). Relative affinities of serum antibodies were evalu-
ated by using altered ligand density ELISA as described
earlier [27].
Flow cytometry analysis
Cell suspensions prepared from spleens excised from mice
on day 9 after immunizations were depleted of erythro-
cytes by ammonium chloride For four-color cell surface
staining, 2 × 106 cells resuspended in PBS containing 2%
BSA were incubated with pre-titered dilutions of GL7-
FITC, biotinylated anti-IgD, anti-B220-PET-Texas Red,
and 2.4 G2-PE for 30 min at 4°C. SA Red 670 was used as
a second-step reagent. Cells were analyzed using a FACS
Calibur cytometer (Becton-Dickinson, Mountain View,
California, USA), and the data were analyzed by FlowJo
software (FlowJo, Ashland, Oregon, USA).
Immunohistochemistry
Spleen isolation, flash freezing, sectioning, and immuno-
histochemistry were all conducted essentially as described
previously [28]. GC numbers were determined by count-
ing the number of PNA+ structures at 10× magnification.
In Vivo Cytotoxicity Assay
C57BL/6 female and male mice, age 8 ~10 weeks, were
used for in vivo cytotoxicity assays. Female mice were
immunized i.p. with syngeneic C57BL/6 male splenocytes
(1 × 107 in 100 μl PBS) at day 0 and boosted at day 10 to
generate anti-H-Y cytotoxic T cells. The in vivo CTL assay
was performed as described earlier with some modifica-
tions [29] Target cells were prepared and adoptively trans-
ferred to recipient female mice at day 18 post priming and
specific killing of target H-Y+ cells was analyzed at day 19.
Briefly, male and female C57BL/6 naïve splenocytes were
isolated and depleted of erythrocyte with RBC lysis buffer
(Sigma-Aldrich, St. Louis, MO, USA). The splenocytes
were washed 1× with 10% FBS RPMI 1640 and 2× with
PBS. The cell densities were adjusted to 2×107 cells/ml.
Male splenocytes were labeled with a high concentration
(5  μM) of 5,6-carboxy-fluorescein succinimdyl ester
(CFSE, Molecular Probes, Eugene, OR, USA), and the
female splenocyte were labeled with low CFSE (0.5 μM).
CFSE labeling was carried out by incubating 2 × 107 cells/
ml in PBS with CFSE at 37°C in a 5% CO2 incubator for
10 min and quenched by adding 10% FBS RPMI to a final
volume of 50 ml. Cells were washed 1× with 10%FBS
RPMI and 2× with PBS to remove free CFSE. Male and
female splenocytes were mixed 1:1 in PBS for the adoptive
transfer. 106 cells in 200 μl PBS were injected into recipi-
ent female mice via tail vein injection. Similar amounts of
cell were injected into the control unimmunized female
mice. Spleens from the recipient mice were harvested after
16 hr, and splenocytes were analyzed for specific killing of
H-Y+ target cells by FACS. At least 5,000 CFSE positive cells
were analyzed. The recovery and percent killing of the
CFSE-labeled targets were calculated as follows:
Data are expressed, as mean ± S.D.
Measurement of antigen-specific T cell recall responses
Anti-MOG responses were induced in 8 to 12-wk-old mice
by immunization with MOG p35–55 in Complete Fre-
und's Adjuvant (CFA). A total of 200 μg of MOG p35–55
peptide and 800 mg of killed Mycobacterium was emulsi-
fied in CFA and injected S.C. by means of four injections
over the flanks. In addition, 200 ng of pertussis toxin dis-
solved in 200 μl of PBS was injected i.p. at the day of
immunization and again the day after [30]. The draining
lymph node and spleen were extracted at day 9 and cell
proliferation assessed with 3[H]-thymidine incorporation
upon stimulation with different concentrations of MOG
peptide (0, 0.5, 5 and 50 μg/ml). Anti-Ova T cells
responses were generated by immunizing the mice with
100 μg of ova in alum in 200 μl volume i.p. The draining
lymph nodes and spleen were harvested at day 9 and cells
were re-stimulated in vitro with varying concentrations of
ova (0, 0.1, 0.5 and 1 mg/ml). Proliferation was measured
as described above. IL-2 in the supernatant was measured
by an R&D Systems ELISA kit according to manufacturer's
instructions
Statistical analysis
Significant differences were determined using one way
ANOVA analysis. A p-value of < 0.05 was considered to be
statistically significant.
Results
Intact T cell-dependent antibody responses in DPP-IV 
knockout mice
The CD26-/- mice were generated as described earlier [23].
Briefly, exons 1 and 2 were replaced with neomycin which
led to elimination of CD26 expression on the surface as
determined by FACS. There was no DPP-4 enzyme activity
detected in the plasma of these mice. DPP-IV knockout
animals had no major differences in the leukocytes popu-
lations in spleen, thymus and blood as compared to their
wild type controls (data not shown). DPP-IV null mice
and their wild type littermate control animals were immu-
nized with NP-CGG in alum and the primary humoral
immune response was measured at day 21 (Figure 1). The
animals were boosted at day 32 with NP-CGG in PBS to
measure secondary humoral immune response 10 days
later. The primary anti-NP response is dominated by λ
Ratio Percentage of female-CFSE low percentage of male-CFS = /E E-high.
%{ [ /  specific lysis ratio from un-immunized ratio from im =− 1m munized]} . ×100BMC Immunology 2009, 10:19 http://www.biomedcentral.com/1471-2172/10/19
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bearing antibodies and B cells that make these antibodies
are recruited into the memory compartment. These mem-
ory B cells secrete high affinity antibodies upon re-chal-
lenge with antigen. There were no differences observed in
the primary and secondary anti NP λ-responses between
the DPP-IV null and wild type control animals (Figure
1A). These antibodies in the secondary responses were
predominantly of high affinity as determined by the
altered ligand density assay [27] in which antibody titers
are assayed by ELISA using different hapten (NP) density
capture (Figure 1D). Higher affinity antibodies bind high
and low NP-capture plates equally well and hence the
ratio of titers is close to 1. Lower affinity antibodies bind
better to high NP-coated plates compared to low NP-
coated plates and hence the ratio of titers are < 1. There
were no differences observed in the dominant anti-NP
lambda bearing or IgG1 antibody titers between the two
groups of animals during the primary or secondary anti-
NP response (Figure 1A &1B). Furthermore affinity
matured antibodies produced by memory B cells upon
boosting were equivalent between the two groups as
measured by the ratio of titers on NP2/NP25. Antibody
titers to the carrier protein CGG are dominated by the G1
bearing heavy chain and these were unaltered in the DPP-
IV null animals (Figure 1C). All the other isotypes were
also unaltered in the DPP-IV null mice as compared to the
control animals (data not shown). Equivalent responses
were also observed between the CD26 null and control
animals immunized with NP-Ova and unconjugated Ova
(data not shown). These results indicate intact antigen
Primary and secondary immune responses to T cell-dependent antigen are intact in DPP IV null and inhibitor treated mice Figure 1
Primary and secondary immune responses to T cell-dependent antigen are intact in DPP IV null and inhibitor 
treated mice. Groups of C57BL/6, DPP IV null and C57BL/6 mice fed with chow containing inhibitor (n = 8) were immunized 
with NP-CGG in alum and bled various time thereafter and their sera analyzed for anti-NP λ (A), IgG1 (B) or anti-CGG IgG1 
(C) titers by ELISA as described in Methods and Materials. The values shown for titers are units defined as EC50 of dilution fac-
tor × 100. (D) Represents the ratio of anti-NP λ bearing antibody titers obtained on NP2-BSA versus NP25-BSA coated plates. 
These data are representative of 3 independent experiments.
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specific T cell-dependent antibody responses in the DPP-
IV-/- animals.
We also investigated whether germinal center (GC) reac-
tions were dependent on DPP-IV. Germinal centers are
secondary lymphoid structures formed in response to
antigen and are obligately dependent on the presence of
helper T cells and B cells during the anti-NP humoral
responses [31]. Splenic GC were evaluated in mice 9 days
post immunization. The size of the GC response was eval-
uated by enumerating GL7+ GC B cells by FACS [32] and
the number of germinal centers via IHC (Figure 2). There
were no differences in the overall GC reactions as deter-
mined by size, frequency (IHC) or numbers of GC B cells
(FACS) in DPP-IV-/- mice as compared to control animals.
Therefore the data indicate that the T cell-dependent anti-
body responses in DPP-IV-/- animals are intact.
Intact T cell-dependent antibody responses in mice treated 
with a highly selective DPP-IV inhibitor
Pharmacological inhibition of DPP-IV was achieved with
a highly selective compound des-fluro sitagliptin (Table
1). Des-fluoro-sitagliptin has properties that are virtually
indistinguishable from sitagliptin itself [33]. Indeed, it
differs from sitagliptin by only 1 fluorine molecule. This
compound does not inhibit DPP-8,-9, Proline dipepti-
dase, Prolyl endopeptidase, Fibroblast activation protein,
Amino peptidase P and Prolidase at >10 μM [15,24] the
compound (des-fluro sitagliptin) was milled into rodent
chow at ~400 mg/kg. This concentration of compound
was sufficient to give >90% inhibition of DPP-IV enzyme
activity that was sustained for 24 hours (Table 2). Similar
to the DPP-IV-/- animals, the total anti-NP response as
measured by λ-bearing and G1 isotype were unaltered in
animals with pharmacological inhibition of the DPP-IV
enzyme activity (Figure 1A &1B). Moreover, the ability to
produce high affinity antibodies from memory B cell
stimulation was intact in drug treated animals as observed
from the ratios of NP2/NP25 ELISA (Figure 1D). The titers
of other isotypes (data not shown) and anti-CGG IgG1
were similar in the drug treated and control animals (Fig-
ure 1C). These data therefore show that there are no dif-
ferences in the amplitude or quality of antibody responses
between C57BL/6 controls or drug treated animals. There-
fore pharmacological blockade of the DPP-IV enzyme
activity has no effect on the primary and secondary T cell-
dependent antibody responses to model antigens.
Intact T cell recall responses in DPP-IV knockout or 
inhibitor-treated mice
Wild type and DPP-IV-/- mice were immunized i.p. with
ovalbumin in alum and the draining mesenteric lymph-
node T cells were stimulated with various concentrations
of Ova in vitro (Figure 3). T cells from the DPP-IV-/- mice
proliferated in a dose dependent manner to Ova which
were similar to that observed in the wild type animals
(Figure 3A). In addition, there was no difference observed
in the amounts of IL-2 produced between the two groups
(Figure 3B).
Recently, it has been reported that the T cell proliferative
recall responses to MOGp35–55 peptide were higher in
DPP-IV-/- mice as compared to the wild type controls [30].
In contrast to this report, our data did not reveal any
enhancement of T cell responses upon re-stimulation with
MOGp35–55 in draining lymph node (Figure 4A) or
splenic cells (Figure 4B) in mice with genetic ablation or
pharmacological inhibition of DPP-IV activity. This is
consistent with our data showing intact T cell recall
responses to Ova in DPP-IV-/- mice.
Intact cytotoxic T cell responses in DPP-IV knockout or 
inhibitor treated mice
In order to evaluate a potential role for DPP-IV in CD8 T
cell function, cytotoxicity was measured using an in vivo
CTL assay with target cells expressing a minor MHC mis-
match (Figure 5). Female mice where primed with the
male cells from the same genetic background leading to
mismatches in the male (H-Y) antigen expressed on these
cells. The primed mice were challenged with a 1:1 mixture
of differentially CFSE-labeled male and female cells. The
Germinal center reaction during the T cell-dependent  immune response is unaltered in DPP IV knock out animals Figure 2
Germinal center reaction during the T cell-depend-
ent immune response is unaltered in DPP IV knock 
out animals. Spleens were extracted on day 9 from animals 
(n = 3) immunized with NP-CGG in alum. Spleens were 
weighed and divided into two parts. One part was used for 
FACS analysis and other for immunohistochemistry. PNA+ 
GC structures were counted from three random 10× fields/
animals. The total numbers of GL-7+ B220+IgD- GC cells/
spleen were enumerated as described in Materials and Meth-
ods. These data are representative of 2 independent experi-
ments.
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CD8 cytotoxic T cells generated should only kill the male
cells and the killing of female cells serves as control to
document non-specific cytotoxicity. There were no differ-
ences observed in the CD8 T cell cytotoxicity between the
wild type, DPP-IV-/- and inhibitor treated wild type ani-
mals. All the three groups demonstrated ~67% killing of
male cells (Figure 6). As a positive control, FK506, a well
characterized T cell immunosuppressant, dosed on (days
-1, 0, +1) during priming and boosting showed a statisti-
cally significant decrease in CD8 T cell mediated killing of
male cells (40%) as compared to untreated wild type ani-
mals. These results demonstrate that genetic ablation of
DPP-IV or pharmacological inhibition of DPP-IV enzyme
activity did not alter CD8 T cell cytotoxicity.
Discussion
Inhibition of DPP-IV is an effective therapy for type II dia-
betes. Since this protein is also expressed on the surface of
T cells, it is conceivable that DPP-IV inhibitors could have
immunomodulatory activity. This possibility was tested
by assessing T cell-dependent immune responses in pre-
clinical models using both DPP-IV knockout mice and
mice treated with a highly selective DPP-IV inhibitor. This
inhibitor, des-fluro sitagliptin, has no activity against
other dipeptidyl peptidases including DPP-2, DPP-8 and
DPP-9 (IC50>10 μM). Several distinct types of assays were
used to evaluate in vivo T cell-dependent responses after
antigen challenge including measurements of serum anti-
body titers, T cell recall responses, and cytotoxic T cell kill-
ing activity. We found that loss of DPP-IV activity had no
significant effect in any of these T cell-dependent immune
response assays.
DPP-IV knockout animals did not show any difference in
the kinetics, amplitude or quality of antigen specific anti-
body responses to a hapten or the protein CGG. In addi-
tion, the germinal center reaction, affinity maturation and
isotype switching of antibodies, all obligately dependent
on T cell help, were similar in wild type and DPP-IV
knockout animals. Moreover, treatment of animals with a
DPP-IV inhibitor did not alter any of the parameters
described above showing that DPP-IV enzyme activity is
not essential for mounting T cell- dependent antibody
responses.
Recently it has been reported that DPP-IV knockout mice
T cell exhibited enhanced proliferative responses to a self
peptide MOGp35–55 [30]. Despite using similar experi-
mental procedures, our results failed to reproduce these
observations in two independent experiments. In addi-
tion, treatment of mice with the DPP-IV inhibitor, des-
fluro sitagliptin, did not have any significant effect on
MOG-specific T cell recall responses. The reason for this
discrepancy is uncertain. Of note, the lack of effect of
DPP-IV inhibition on MOG-specific immune responses is
similar to results seen for other protein antigens such as
CGG and Ova. These results strongly suggest that DPP-IV
does not play a significant role in T cell recall responses to
protein antigens.
CD8 T cells play an important role in immunity against
intracellular pathogens. We investigated the effects of
DPP-IV blockade on in vivo cytotoxic T cell functions by
challenging the female mice with male cells to generate H-
Y specific cytotoxic T cells. The primed animals challenged
with male cells demonstrated equivalent cytotoxicity
when the DPP-IV expression was genetically ablated or the
DPP-IV enzyme activity blocked with des-fluro sitagliptin
in comparison to the wild type animals (Figure 6). These
results indicate that the CD8 T cell cytotoxic function is
intact in animals with DPP-IV blockade.
Table 1: Properties of Des-flurositagliptin
IC50 hDPP-IV IC50 hDPP-8 IC50 hDPP-9 IC50 mDPP-IV IC50 hDPP-2
27 nM >10 μM> 1 0   μM9 7  n M> 1 0  μM
Table 2: Des-flurositagliptin dosed at ~400 mpk in feed is able to inhibit the DPP IV enzyme activity for 24 hours in blood.
Conversion of substrate in nmol/min
Day 1 Day 2 Day 3
Des-flurositagliptin, am bleed 4.53 ± 0.22 5.44 ± 0.79 6.12 ± 0.48
Des-flurositagliptin, pm bleed 4.90 ± 0.37 8.08 ± 1.8 8.29 ± 1.42
Control, am bleed 39.8 ± 4.0 47.5 ± 5.23 40.1 ± 6.94
Control, pm bleed 31.4 ± 0.65 43.3 ± 6.01 40.3 ± 7.65
DPP-IV-/- mice 1.02 ± 0.51
The animals were fed chow milled with 6.7 grams of desflurositagliptin in 1 kg of Tekland chow to deliver an effective dose of 400 mpk. Blood were 
drawn 12 hours apart and DPP IV enzyme activity measured as described earlier. The animals (n = 4 in each group) were maintained on the 
inhibitor for the entire period of the experiment.BMC Immunology 2009, 10:19 http://www.biomedcentral.com/1471-2172/10/19
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Our data add to and extend the earlier observation that
the DPP-IV enzyme activity is not required for T cell acti-
vation or co-stimulating properties in vitro  [8,34-37].
Busso et al have observed no effects of CD26 deficiency on
in vitro or in vivo proliferation of lymph node and spleen
cells nor on in vivo antibody response to mBSA immuni-
zation [38]. Furthermore, although lower IgG1 and IgG2a
titers were found in CD26 knockout animals as compared
to wild type mice immunized with poke weed mitogen
(PWM) in the primary response [10] these differences
were eliminated upon boosting with PWM. Earlier reports
assessing the effect of DPP-IV on T cell functions have
used inhibitors that were non-selective against other
dipeptidyl peptidases [16-18,21,39]. The compound des-
fluro sitagliptin used in the current studies is structurally
similar to sitagliptin, a highly selective DPP-IV inhibitor
that is approved for clinical use in type II diabetic patients.
We have previously shown that highly selective DPP-IV
inhibitors do not impair T cell activation in vitro, in con-
trast to less selective inhibitors that cross-inhibit DPP8
and DPP9 [15]. The current studies extend these observa-
tions by showing that highly selective inhibition of DPP-
IV does not disrupt T cell responses in vivo.
While DPP-IV does not appear to affect T cell-dependent
responses, this protein could modulate other types of
immune responses. For example, in humans, DPP-IV is
reported to associate with adenine deaminase (ADA) on
the surface of the T cell and could prevent the inhibitory
effects of adenosine on T cell proliferation [40]. The crys-
tal structures of both the sitagliptin/DPP-IV complex and
the ADA/DPP-IV complex have been solved. While sit-
agliptin binds DPP-IV to inhibit its enzymatic activity
[41], this binding does not alter the overall conformation
of the DPP-IV molecule, including the aspect of the mole-
cule that binds to ADA [42]. Therefore, sitagliptin is
highly unlikely to alter the ADA-binding properties of
DPP-IV. However, since the CD26 molecule does not
associate with ADA in mice its impact on T-cell function
cannot be addressed in rodents [43]. DPP-IV has also been
reported to associate with CD45 and could thereby mod-
ulate signal transduction [44]. We did not directly address
functions that could be altered by disrupting the cell sur-
face association of CD45 with DPP-IV. Of note, inhibition
of DPP-IV enzymatic activity would not be expected to
affect the association of DPP-IV with other cell surface
proteins. Our studies focus on the role of DPP-IV in in vivo
T-cell functions. Several studies including work done by
Morimoto et al has implicated potentially diverse roles for
DPP-IV in human T-cell functions. For instance expres-
sion of CD26 on T-cells has been associated with co-stim-
ulatory functions [45]. Studies performed by this group
have used isolated T-cells stimulated in vitro in a variety of
ways (including with anti-CD26 antibody, recombinant
soluble CD26, and an Fc-caveolin-1 fusion protein).
Indeed, the more recent results from this group focus on
Ex-vivo T cell recall responses to Ovalbumin are equivalent in DPP IV null and wild type animals Figure 3
Ex-vivo T cell recall responses to Ovalbumin are equivalent in DPP IV null and wild type animals. Wild type 
(open square) and DPP IV KO (filled square) animals (n = 3) were immunized with Ova in alum and draining mesenteric lymph 
nodes were harvested on day 9. Cells were than re-stimulated with various concentrations of Ova in vitro and a) proliferation 
and b) IL-2 production measured by [3H] thymidine incorporation and ELISA respectively as described in Methods and Materi-
als. Wild type and DPP-IV KO unstimulated cell proliferation was 843 ± 244 and 908 ± 779 cpm respectively. These data are 
representative of 2 independent experiments.
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dissecting in vitro protein-protein interactions and signal-
ing by the CD26 molecule and its putative ligand, caveo-
lin-1. DPP-IV was reported to have co-stimulatory activity
in studies using isolated T-cells or T-cell lines stimulated
by cross-linking surface CD26 with antibodies [46]. How-
ever, the physiological relevance of these studies is uncer-
tain, e.g., endogenous cross-linking ligands have not been
identified and, clearly, there is much work to be done to
further establish the potential physiologic role that CD26
might play in immune processes.
Isolated human Th1 cells expressed three to six fold more
CD26 protein than Th2 cells and were more responsive to
anti-DPP-IV cross-linking [47]. Interestingly, DPP-IV
enzyme activities were equivalent in both Th1 and Th2
cells. DPP-IV could have different role in distinct T-cell
populations. The potential role of DPP-IV in other T-Cell
subsets Th17, Treg requires further studies.
It has been previously shown that DPP-IV is capable of in
vitro cleavage of SDF-1α and a number of other chemok-
ines like CXCL6, CXCL9, CXCL10, CXCL11, CCL3L1,
CCL5, CCL11 and CCL22 in vitro  [7,38,48-54]. Recently
it was shown that DPP8 could also cleave CXCL10,
CXCL11 and CXCL12 in vitro [55]. However, whether
cleavage of these chemokines occurs in vivo has yet to be
demonstrated and thus the physiological relevance is
uncertain. DPP-IV-/- mice were found to be resistant to G-
CSF mediated mobilization of hematopoietic stem cell,
suggesting a potential role for DPP-IV in regulating SDF-
1α in the bone marrow [38,48]. This has led to the postu-
lation that DPP-IV inhibitors could be clinical useful for
bone marrow transplantation.
Conclusion
The manuscript provides important data on the role of
DPP-IV on T-cell immune function. Genetic ablation of
DPP-IV or pharmacological inhibition of its enzymatic
activity had no measurable effect on T cell-dependent
immune responses in mice. While there may be limita-
tions regarding extrapolation of the results to humans,
these results are consistent with the favorable clinical
experience with sitagliptin, to date.
Ex-vivo anti-MOGp35–55 peptide responses are unaltered in wild type, DPP IV null and des-flurositagliptin treated animals Figure 4
Ex-vivo anti-MOGp35–55 peptide responses are unaltered in wild type, DPP IV null and des-flurositagliptin 
treated animals. Proliferative response to MOG p35–55 of MOG primed T cells from wild-type (filled triangle), DPP IV null 
(inverted triangle) and des-flurositagliptin (filled diamond) treated animals (n = 4) from draining mesenteric lymph node (A) and 
spleen (B). Cells were isolated day 11 following immunization with MOG p35–55 in CFA. Cells were cultured with the indi-
cated concentrations of MOG p35–55 for 72 h, and T cell proliferation in each culture was measured using [3H] thymidine 
incorporation assay. The cell proliferation is shown as counts per minute. Proliferation of unstimulated cells from MOG pep-
tide immunized wild type, DPP IV null and wild type+ inhibitor treated mice was 2005 ± 553, 1678 ± 347 and 1876 ± 599 cpm 
respectively. These data are representative of 2 independent experiments.
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